This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction: A New Era in the Pharmacotherapy of Psychotic Disorders

Alan Breier, MD

Published: February 1, 2001

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Schizophrenia and related psychotic disorders are debilitating illnesses affecting approximately 1% of theworld population. These illnesses are generally chronic, beginning early in life and persisting into the elderly years. The impact of the illnesses on affected individuals and their families is monumental. The positive symptoms of schizophrenia lead to disruption of coherent thinking, anxiety, and distress that make day-to-day functioning challenging.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: Neurologic and Neurocognitive , Neurology

Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...